Product Information

ABACAVIR-LAMIVUDINE 600-300 MG is a generic product labeled by Aurobindo Pharma Limited, priced at $1.4688 per EA under NDC 65862033530. Its NADAC has been published 338 times since Mar 4, 2020.

FDA first approved this application on Nov 15, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ABACAVIR-LAMIVUDINE 600-300 MG

Abacavir and Lamivudine
$1.4688per EA

Strength

600; 300 mg/1; mg/1

NDC

65862033530

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA090159

FDA Approved

11/15/2018

TE Code

AB

On Market Since

11/15/2018

Price Statistics

The NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has been published 338 times since Mar 4, 2020, and over the history we have for it it has declined 51.1%. The table below summarizes its recorded NADAC range and movement.

Current price$1.4688 per EA
All-time high$3.0410 (Nov 11, 2020)
All-time low$1.2091 (Nov 22, 2023)
52-week high$1.6284
52-week low$1.2621
Median price$1.8199
Average price$1.9089
Largest weekly change+64.5% (Nov 23, 2022)
Weeks tracked338
Tracking sinceMar 4, 2020

Price History

1W

+2.4%

1M

+2.4%

3M

+4.6%

6M

+12.3%

1Y

-9.8%

3Y

-27.0%

5Y

-32.8%

All

-51.1%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of ABACAVIR-LAMIVUDINE 600-300 MG?

The current National Average Drug Acquisition Cost (NADAC) for ABACAVIR-LAMIVUDINE 600-300 MG, manufactured by Aurobindo Pharma Limited, is $1.4688 per EA (NDC 65862033530), effective Aug 19, 2026.

How has the price of ABACAVIR-LAMIVUDINE 600-300 MG changed over time?

Over the history we have for it, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has declined 51.1%. It has been tracked across 338 weekly CMS publications since Mar 4, 2020.

What are the highest and lowest recorded NADAC prices for ABACAVIR-LAMIVUDINE 600-300 MG?

Since Mar 4, 2020, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has ranged from a low of $1.2091 (Nov 22, 2023) to a high of $3.0410 (Nov 11, 2020), with a median of $1.8199 per EA.

Are there cheaper alternatives to ABACAVIR-LAMIVUDINE 600-300 MG?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ABACAVIR-LAMIVUDINE 600-300 MG in a comparable dosage form, but none are currently priced below it.

Who manufactures ABACAVIR-LAMIVUDINE 600-300 MG?

ABACAVIR-LAMIVUDINE 600-300 MG (NDC 65862033530) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.